EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Is drug interference still an issue for pretransfusion testing of patients on anti CD38 and other monoclonal antibody therapies?

Nichole Bevel, Meagan Thorpe, Thiru Vanniasinkam iD

Vox Sanguinis · 2024

DOI: 10.1111/vox.13649 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Vox Sanguinis, 2024. Verfasst von Nichole Bevel und 2 weiteren Autor:innen. Beteiligte Einrichtung: School of Dentistry and Medical Sciences, Charles Sturt University, Wagga Wagga, New South Wales, Australia. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, ADP-ribosyl Cyclase 1. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Certain therapies that target CD markers on some blood cells can affect pretransfusion testing. Key examples are anti‐CD38, CD47 monoclonal antibody (mAb) therapies such as daratumumab (DARA) and magrolimab, which have presented a challenge for transfusion medicine laboratories around the globe. Scientists have been faced with not only introducing a protocol to provide safe blood to patients but also investigating the most effective method to remove the pretransfusion pan‐agglutinating interference caused. A number of papers in the last 5 years have reported on various methods to remove pretransfusion interference; however, most of these studies have been conducted only in a few countries. Most recent reviews on this topic have focused on techniques and reagents to remove pretransfusion interference, and dithiothreitol is currently the gold standard for removing DARA interference. However, it was clear from this review that while many laboratories have developed processes for addressing interference in pretransfusion testing, and DARA interference may not be a major issue, there are still laboratories around the world, that may not have adequately addressed this issue. In addition, the impact of mAb interference on widely used techniques such as flow cytometry is unclear.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalADP-ribosyl Cyclase 1HumansBlood TransfusionMembrane GlycoproteinsCD47 AntigenFlow Cytometry

Stichwörter der Autor:innen

DTTdaratumumabinterferencepretransfusiontransfusion medicine laboratories

Substanzen

Antibodies, MonoclonalADP-ribosyl Cyclase 1daratumumabCD38 protein, humanMembrane GlycoproteinsCD47 Antigen

Autor:innen und Institutionen

  • School of Dentistry and Medical Sciences, Charles Sturt University, Wagga Wagga, New South Wales, Australia.
  • Transfusion Medicine Laboratory, St Vincent's Hospital, Sydney, New South Wales, Australia.

ORCID-Profile: Thiru Vanniasinkam

Zitieren

APA

Bevel, N., Thorpe, M., & Vanniasinkam, T. (2024). Is drug interference still an issue for pretransfusion testing of patients on anti CD38 and other monoclonal antibody therapies?. Vox Sanguinis. https://doi.org/10.1111/vox.13649

Vancouver

Bevel N, Thorpe M, Vanniasinkam T. Is drug interference still an issue for pretransfusion testing of patients on anti CD38 and other monoclonal antibody therapies?. Vox Sanguinis. 2024. doi:10.1111/vox.13649

BibTeX
@article{Bevel2024,
  author = {Bevel, Nichole and Thorpe, Meagan and Vanniasinkam, Thiru},
  title = {Is drug interference still an issue for pretransfusion testing of patients on anti CD38 and other monoclonal antibody therapies?},
  journal = {Vox Sanguinis},
  year = {2024},
  doi = {10.1111/vox.13649}
}
Kostenlos starten →